All around suboptimal health - a joint position paper of the Suboptimal Health Study Consortium and European Association for Predictive, Preventive and Personalised Medicine
© The Author(s) 2021..
First two decades of the twenty-first century are characterised by epidemics of non-communicable diseases such as many hundreds of millions of patients diagnosed with cardiovascular diseases and the type 2 diabetes mellitus, breast, lung, liver and prostate malignancies, neurological, sleep, mood and eye disorders, amongst others. Consequent socio-economic burden is tremendous. Unprecedented decrease in age of maladaptive individuals has been reported. The absolute majority of expanding non-communicable disorders carry a chronic character, over a couple of years progressing from reversible suboptimal health conditions to irreversible severe pathologies and cascading collateral complications. The time-frame between onset of SHS and clinical manifestation of associated disorders is the operational area for an application of reliable risk assessment tools and predictive diagnostics followed by the cost-effective targeted prevention and treatments tailored to the person. This article demonstrates advanced strategies in bio/medical sciences and healthcare focused on suboptimal health conditions in the frame-work of Predictive, Preventive and Personalised Medicine (3PM/PPPM). Potential benefits in healthcare systems and for society at large include but are not restricted to an improved life-quality of major populations and socio-economical groups, advanced professionalism of healthcare-givers and sustainable healthcare economy. Amongst others, following medical areas are proposed to strongly benefit from PPPM strategies applied to the identification and treatment of suboptimal health conditions:Stress overload associated pathologiesMale and female healthPlanned pregnanciesPeriodontal healthEye disordersInflammatory disorders, wound healing and pain management with associated complicationsMetabolic disorders and suboptimal body weightCardiovascular pathologiesCancersStroke, particularly of unknown aetiology and in young individualsSleep medicineSports medicineImproved individual outcomes under pandemic conditions such as COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
The EPMA journal - 12(2021), 4 vom: 26. Dez., Seite 403-433 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Wei [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 02.11.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1007/s13167-021-00253-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33081835X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33081835X | ||
| 003 | DE-627 | ||
| 005 | 20231225212114.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13167-021-00253-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1102.xml |
| 035 | |a (DE-627)NLM33081835X | ||
| 035 | |a (NLM)34539937 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Wei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a All around suboptimal health - a joint position paper of the Suboptimal Health Study Consortium and European Association for Predictive, Preventive and Personalised Medicine |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.11.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2021. | ||
| 520 | |a First two decades of the twenty-first century are characterised by epidemics of non-communicable diseases such as many hundreds of millions of patients diagnosed with cardiovascular diseases and the type 2 diabetes mellitus, breast, lung, liver and prostate malignancies, neurological, sleep, mood and eye disorders, amongst others. Consequent socio-economic burden is tremendous. Unprecedented decrease in age of maladaptive individuals has been reported. The absolute majority of expanding non-communicable disorders carry a chronic character, over a couple of years progressing from reversible suboptimal health conditions to irreversible severe pathologies and cascading collateral complications. The time-frame between onset of SHS and clinical manifestation of associated disorders is the operational area for an application of reliable risk assessment tools and predictive diagnostics followed by the cost-effective targeted prevention and treatments tailored to the person. This article demonstrates advanced strategies in bio/medical sciences and healthcare focused on suboptimal health conditions in the frame-work of Predictive, Preventive and Personalised Medicine (3PM/PPPM). Potential benefits in healthcare systems and for society at large include but are not restricted to an improved life-quality of major populations and socio-economical groups, advanced professionalism of healthcare-givers and sustainable healthcare economy. Amongst others, following medical areas are proposed to strongly benefit from PPPM strategies applied to the identification and treatment of suboptimal health conditions:Stress overload associated pathologiesMale and female healthPlanned pregnanciesPeriodontal healthEye disordersInflammatory disorders, wound healing and pain management with associated complicationsMetabolic disorders and suboptimal body weightCardiovascular pathologiesCancersStroke, particularly of unknown aetiology and in young individualsSleep medicineSports medicineImproved individual outcomes under pandemic conditions such as COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adolescence | |
| 650 | 4 | |a Artificial intelligence (AI) | |
| 650 | 4 | |a Behavioural patterns | |
| 650 | 4 | |a Big data management | |
| 650 | 4 | |a Body mass index (BMI) | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Cancers | |
| 650 | 4 | |a Cardiovascular disease | |
| 650 | 4 | |a Communicable | |
| 650 | 4 | |a Dietary habits | |
| 650 | 4 | |a Epidemics | |
| 650 | 4 | |a Glycan | |
| 650 | 4 | |a Health economy | |
| 650 | 4 | |a Health policy | |
| 650 | 4 | |a Individualised patient profile | |
| 650 | 4 | |a Lifestyle | |
| 650 | 4 | |a Liquid biopsy | |
| 650 | 4 | |a Medical ethics | |
| 650 | 4 | |a Microbiome | |
| 650 | 4 | |a Modifiable preventable risks | |
| 650 | 4 | |a Mood disorders | |
| 650 | 4 | |a Multi-level diagnostics | |
| 650 | 4 | |a Multi-parametric analysis | |
| 650 | 4 | |a Natural substances | |
| 650 | 4 | |a Neurologic diseases | |
| 650 | 4 | |a Non-communicable diseases | |
| 650 | 4 | |a Omics | |
| 650 | 4 | |a Pandemics | |
| 650 | 4 | |a Periodontal health | |
| 650 | 4 | |a Predictive preventive personalised medicine (PPPM/3PM) | |
| 650 | 4 | |a Risk assessment | |
| 650 | 4 | |a Sleep medicine | |
| 650 | 4 | |a Stress overload | |
| 650 | 4 | |a Suboptimal health status (SHS) | |
| 650 | 4 | |a Traditional medicine | |
| 700 | 1 | |a Yan, Yuxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Zheng |e verfasserin |4 aut | |
| 700 | 1 | |a Hou, Haifeng |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia, Monique |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Xuerui |e verfasserin |4 aut | |
| 700 | 1 | |a Anto, Enoch Odame |e verfasserin |4 aut | |
| 700 | 1 | |a Mahara, Gehendra |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Yulu |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Timothy |e verfasserin |4 aut | |
| 700 | 1 | |a Zhong, Zhaohua |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Youxin |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Xiuhua |e verfasserin |4 aut | |
| 700 | 1 | |a Golubnitschaja, Olga |e verfasserin |4 aut | |
| 700 | 0 | |a Suboptimal Health Study Consortium and European Association for Predictive, Preventive and Personalised Medicine |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The EPMA journal |d 2010 |g 12(2021), 4 vom: 26. Dez., Seite 403-433 |w (DE-627)NLM204043042 |x 1878-5077 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2021 |g number:4 |g day:26 |g month:12 |g pages:403-433 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s13167-021-00253-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2021 |e 4 |b 26 |c 12 |h 403-433 | ||